Skip to content

EBITDA at other companies

CG Oncology logo
CG OncologyCGON
-$65.55M-55.4%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
-$78.09M+6.7%
Celcuity logo
CelcuityCELC
-$50.46M-39.8%
Pfizer logo
PfizerPFE
Amgen logo
AmgenAMGN
Incyte logo
IncyteINCY

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$5.9B+816%

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Calculated from Cogent Biosciences, Inc.’s reported figures.

$103.6Mebit+
$626.0KDepreciation Depletion & Amortization
=-$102.98M

The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cogent Biosciences, Inc.'s EBITDA?
Cogent Biosciences, Inc. (COGT) reported EBITDA of -$102.98M in Q1 2026.
How has Cogent Biosciences, Inc.'s EBITDA changed year-over-year?
Cogent Biosciences, Inc.'s EBITDA decreased by 38.6% year-over-year, from -$74.29M to -$102.98M.
What is the long-term trend for Cogent Biosciences, Inc.'s EBITDA?
Over 4 years (2021 to 2025), Cogent Biosciences, Inc.'s EBITDA has grown at a 44.7% compound annual growth rate (CAGR), from -$75.4M to -$330.79M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.